-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $44

Benzinga·11/06/2025 16:22:41
Listen to the news
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $39 to $44.